Reply to S. Boutayeb et al.

JCO Oncol Pract

Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC.

Published: August 2020

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00394DOI Listing

Publication Analysis

Top Keywords

reply boutayeb
4
reply
1

Similar Publications

[Evaluation of the practice of prescribing oral chemotherapy type "Capecitabine" by medical oncologist: A first study from Morocco].

Bull Cancer

October 2021

Université Mohamed-V suissi, institut nationale d'oncologie, faculté de médecine et de Pharmacie de Rabat, service d'oncologie médicale, Rabat, Maroc.

Introduction: Oral anticancer therapy is becoming increasingly developed; their prescription has become a common practice in oncology. However, there is a variability and diversity in prescription practice. Its magnitude has been very little studied in scientific literature.

View Article and Find Full Text PDF

Reply to S. Boutayeb et al.

JCO Oncol Pract

August 2020

Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC.

View Article and Find Full Text PDF

In Reply.

Oncologist

August 2020

Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.

This letter to the editor remarks on additional considerations for the management of febrile neutropenia during the COVID‐19 pandemic, in response to the letter by Boutayeb et al.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!